{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:09:14Z","timestamp":1781626154021,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82403265 and 82404078"],"award-info":[{"award-number":["No. 82403265 and 82404078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["No. 2023A1515110701"],"award-info":[{"award-number":["No. 2023A1515110701"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06461-5","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:59:47Z","timestamp":1774637987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"152","author":[{"given":"Sijian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingna","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"6461_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1200\/JCO.22.02915","volume":"42","author":"RC Arend","year":"2024","unstructured":"Arend RC, Monk BJ, Shapira-Frommer R et al (2024) Ofranergene Obadenovec (Ofra-Vec, VB-111) with weekly Paclitaxel for platinum-resistant ovarian cancer: randomized controlled Phase III trial (OVAL Study\/GOG 3018). J Clin Oncol 42:170\u2013179","journal-title":"J Clin Oncol"},{"key":"6461_CR2","first-page":"675","volume":"9","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Giannone G, Clamp AR et al (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2. Random Clin Trial JAMA Oncol 9:675\u2013682","journal-title":"Random Clin Trial JAMA Oncol"},{"key":"6461_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"6461_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2017.11.008","volume":"148","author":"M Champer","year":"2018","unstructured":"Champer M, Huang Y, Hou JY et al (2018) Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol 148:19\u201327","journal-title":"Gynecol Oncol"},{"key":"6461_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K et al (2023) Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol 9:465\u2013472","journal-title":"JAMA Oncol"},{"key":"6461_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","volume":"122","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Brady WE, McMeekin DS et al (2011) A Phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 122:111\u2013115","journal-title":"Gynecol Oncol"},{"key":"6461_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020. Ann Oncol 30:672\u2013705","journal-title":"Ann Oncol"},{"key":"6461_CR8","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.62347\/OMOR8605","volume":"17","author":"J Deng","year":"2025","unstructured":"Deng J, Cai Y, Liao J et al (2025) Effects of nedaplatin combined with paclitaxel liposomes or docetaxel on survival rate and biomarkers in patients with recurrent ovarian cancer. Am J Transl Res 17:2484\u20132499","journal-title":"Am J Transl Res"},{"key":"6461_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"6461_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ygyno.2015.09.011","volume":"139","author":"KH Eng","year":"2015","unstructured":"Eng KH, Hanlon BM, Bradley WH, Szender JB (2015) Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol Oncol 139:228\u2013235","journal-title":"Gynecol Oncol"},{"key":"6461_CR11","first-page":"1074","volume":"8","author":"L Ge","year":"2018","unstructured":"Ge L, Li N, Yuan GW et al (2018) Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. Am J Cancer Res 8:1074\u20131082","journal-title":"Am J Cancer Res"},{"key":"6461_CR12","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"6461_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","volume":"34","author":"C Kurzeder","year":"2016","unstructured":"Kurzeder C, Bover I, Marm\u00e9 F et al (2016) Double-blind, placebo-controlled, randomized Phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol 34:2516\u20132525","journal-title":"J Clin Oncol"},{"key":"6461_CR14","first-page":"3646","volume":"15","author":"L Li","year":"2018","unstructured":"Li L, Zhuang Q, Cao Z et al (2018) Paclitaxel plus Nedaplatin vs. paclitaxel plus Carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. Oncol Lett 15:3646\u20133652","journal-title":"Oncol Lett"},{"key":"6461_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann K, Gao B, Mapagu C et al (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150:239\u2013246","journal-title":"Gynecol Oncol"},{"key":"6461_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ et al (2024) NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw 22:512\u2013519","journal-title":"J Natl Compr Canc Netw"},{"key":"6461_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100009","volume":"35","author":"F Martorana","year":"2025","unstructured":"Martorana F, Pavone G, Sessa C et al (2025) Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer. Int J Gynecol Cancer 35:100009","journal-title":"Int J Gynecol Cancer"},{"key":"6461_CR18","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE et al (2023) Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med 389:2162\u20132174","journal-title":"N Engl J Med"},{"key":"6461_CR19","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"6461_CR20","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","volume":"405","author":"AB Olawaiye","year":"2025","unstructured":"Olawaiye AB, Gladieff L, O\u2019Malley DM et al (2025) Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet 405:2205\u20132216","journal-title":"Lancet"},{"key":"6461_CR21","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F et al (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836\u20133838","journal-title":"J Clin Oncol"},{"key":"6461_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"6461_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM (2023) Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol 9:851\u2013859","journal-title":"JAMA Oncol"},{"key":"6461_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419\u2013423","journal-title":"Int J Gynecol Cancer"},{"key":"6461_CR25","doi-asserted-by":"crossref","unstructured":"Szupryczy\u0144ski K, Szefler B (2025) Interactions of nedaplatin with nucleobases and purine alkaloids: their role in cancer therapy. Biomedicines 13","DOI":"10.3390\/biomedicines13071551"},{"key":"6461_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2012.08.039","volume":"128","author":"TD Tillmanns","year":"2013","unstructured":"Tillmanns TD, Lowe MP, Walker MS et al (2013) Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 128:221\u2013228","journal-title":"Gynecol Oncol"},{"key":"6461_CR27","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s10147-025-02817-y","volume":"30","author":"L Vertechy","year":"2025","unstructured":"Vertechy L, Ergasti R, Chiamenti C et al (2025) Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis. Int J Clin Oncol 30:1873\u20131881","journal-title":"Int J Clin Oncol"},{"key":"6461_CR28","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e71","volume":"35","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Lin Y, Liu K, Zhu H (2024) Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J Gynecol Oncol 35:e71","journal-title":"J Gynecol Oncol"}],"updated-by":[{"DOI":"10.1007\/s00432-026-06528-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000}}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06461-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:48:03Z","timestamp":1781624883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06461-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6461"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06461-5","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, two instances of \u2018bevacizumab (10 mg\/m<sup>2<\/sup>)\u2019 need to be corrected to \u2018bevacizumab 10 mg\/kg\u2019. These errors appear in the Abstract and Materials and Methods (Study design and participants) section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00432-026-06528-3","URL":"https:\/\/doi.org\/10.1007\/s00432-026-06528-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center (reference number: B2025-590-01, date of approval: August 18th, 2025), and all methods were carried out following the Declaration of Helsinki. Written informed consent to participate in the study was waived by the ethics committee due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"76"}}